Stockholm, December 14, 2021 - Intervacc AB ("Intervacc") announces today that sales of the company's Strangles vaccine Strangvac are planned to begin in the first quarter of 2022.
Intervacc's vaccine against equine Strangles, a widespread and common infectious disease that affects horses globally, was granted marketing authorization for the European Union in the autumn, followed by approvals for the United Kingdom, Norway and Iceland.
"We have produced vaccine for launch in Sweden and European markets. Production has gone well and we expect the vaccine doses to be released in January 2022", explains Dr. Tim Wood head of CMC and regulatory at Intervacc.
"In preparation for the launch we have held meetings with leading European Equine veterinarians and the response has been fantastic", says Dr Andrew Waller, Chief Scientific Officer at Intervacc.
"The interest in Strangvac is already very large and we have been contacted by many horse owners in Sweden and in the rest of Europe who want to vaccinate their horses against Strangles as soon as Strangvac is available for sale." says Andreas Andersson, CEO of Intervacc.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on December 14, 2021.
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, firstname.lastname@example.org,+46 (0)8-684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: email@example.com,Phone: +46 (0)8 - 684 211 10
This information was distributed by Cision http://www.cisionwire.se/